SC 13G: Inhibikase Therapeutics, Inc.

AI Summary

SC 13G filing by Inhibikase Therapeutics, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class o

Filing Documents

• d840359dsc13g.htm (SC 13G) — 69KB
• 0001193125-24-244251.txt ( ) — 71KB

From the Filing

SC 13G 1 d840359dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibikase Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45719W205 (CUSIP Number) October 21, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). SCHEDULE 13G CUSIP No. 45719W205 1 Names of Reporting Persons Sands Capital Life Sciences Pulse Fund II, L.P. 2 Check the appropriate box if a member of a Group (see instructions) (a)(b) 3 Sec Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 10,950,000 7 Sole Dispositive Power 0 8 Shared Dispositive Power 10,950,000 9 Aggregate Amount Beneficially Owned by Each Reporting Person 10,950,000 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 16.3% (1) 12 Type of Reporting Person (See Instructions) PN (1) The calculation of beneficial ownership of the Reporting Persons (as defined below) is based on 67,192,570 shares of the Issuers Common Stock (each as defined below) issued and outstanding as of October 21, 2024, as reported by the Issuer to the Reporting Persons (giving effect to 58,310,000 shares of Common Stock sold by the Issuer pursuant to a securities purchase agreement, dated October 9, 2024, as reported by the Issuer in its Current Report on Form 8-K filed on October 10, 2024). SCHEDULE 13G CUSIP No. 45719W205 1 Names of Reporting Persons Sands Capital Ventures, LLC 2 Check the appropriate box if a member of a Group (see instructions) (a)(b) 3 Sec Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 10,950,000 (1) 7 Sole Dispositive Power 0 8 Shared Dispositive Power 10,950,000 (1) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 10,950,000 (1) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 16.3% (2) 12 Type of Reporting Person (See Instructions) OO (1) This amount includes 10,950,000 shares of Common Stock that are beneficially owned by Sands Capital Life Sciences Pulse Fund II, L.P. (Sands Pulse Fund II). Sands Capital Ventures, LLC (Sands Capital Ventures), as the investment manager of Sands Pulse Fund II, may be deemed to beneficially own a total of 10,950,000 shares of Common Stock beneficially owned by Sands Pulse Fund II. (2) The calculation of beneficial ownership of the Reporting Persons is based on 67,192,570 shares of Common Stock issued and outstanding as of October 21, 2024, as reported by the Issuer to the Reporting Persons (giving effect to 58,310,000 shares of Common Stock sold by the Issuer pursuant to a securities purchase agreement, dated October 9, 2024, as reported by the Issuer in its Current Report on Form 8-K filed on October 10, 2024). SCHEDULE 13G CUSIP No. 45719W205 1 Names of Reporting Persons Frank M. Sands 2 Check the appropriate box if a member of a Group (see instructions) (a)(b) 3 Sec Use Only 4 Citizenship or Place of Organization United States of America Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 10,950,000 (1) 7 Sole Dispositive Power 0 8 Shared Dispositive Power 10,950,000 (1) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 10,950,000 (1) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 16.3% (2) 12 Type of Reporting Person (See Instructions) IN (1) This amount includes 10

View Full Filing

View this SC 13G filing on SEC EDGAR